Hycamtin
information and resources from the National Cancer Institute
NCI Thesaurus | Hycamtin
(Other name for: topotecan)NCI Thesaurus | Hycamtin
(Other name for: topotecan)
topotecan
Treatment of patients with metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy.
GlaxoSmithKline May 28 1996
topotecan
Treatment of small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the phase 3 study) or at least 90 days (in the phase 2 studies) after chemotherapy
GlaxoSmithKline Nov 30 1998
|
|
|
|
news articles
International Approvals: Rotarix, Hycamtin, Pulmicort HFA Mar 6, 2006
Medscape (subscription) On February 1, the European Commission (EC) approved a new indication for topotecan HCl powder for infusion solution (Hycamtin, made by GlaxoSmithKline ...
Hana Biosciences to License Three Targeted Cancer Drug Candidates ... Mar 17, 2006
Genetic Engineering News, Topotecan (Hycamtin(R); GlaxoSmithKline), a topoisomerase I inhibitor, is approved for use in relapsed small-cell lung cancer and in relapsed ovarian cancer ...
Hana Paying Up To $42M For Inex’s Cancer Drugs Mar 17, 2006
BioWorld Online (subscription), Topotecan, marketed under the name Hycamtin, also from GSK, is a topoisomerase I inhibitor approved for use in relapsed small-cell lung cancer and relapsed ...
GlaxoSmithKline's Hycamtin receives positive lung cancer opinion ... Nov 24, 2005
Forbes LONDON (AFX) - GlaxoSmithKline PLC said its Hycamtin drug has received a positive opinion on lung cancer treatment from an EU regulatory committee that it said ...
GSK Hycamtin Bolsters But Doesn't Excite>GSK Nov 24, 2005
New Ratings 1132 GMT [Dow Jones] GlaxoSmithKline's (GSK) has announced it has received positive opinion for Hycamtin from the European Committee for Human Medicinal ...
Hycamtin® receives positive opinion in Europe for treatment of ... Nov 28, 2005
Medical News Today (press release), GlaxoSmithKline (GSK) announced that HYCAMTIN® (topotecan powder for concentration for solution for infusion) received positive opinion from the European ...
GlaxoSmithKline announces Hycamtin® receives positive opinion in ... Nov 27, 2005
Chemie.de (press release), 11/28/2005 - GlaxoSmithKline (GSK) announced that HYCAMTIN® (topotecan powder for concentration for solution for infusion) received positive opinion from the ...
Sinotrading/SEO Specialist Lonnie B. Hodge to Market Anti-cancer ... Dec 4, 2005
PR Web (press release), Most people know that a slew of anti-cancer agents are natural in origin: paclitaxel (Taxol), and camptothecin (Hycamtin) among others. ...
Committee for Medicinal Products for Human Use Post-authorisation ... Nov 18, 2005
PharmaLive.com (press release), ...positive opinion,?? to recommend the variation to the terms of the marketing authorisation for the medicinal product Hycamtin. The ...
GlaxoSmithKline Presents Rapidly Expanding Pipeline of Oncology ... Nov 30, 2005
Finanzen.net, ...highlighted at the seminar include Arranon for T-cell acute lymphoblastic leukemia and lymphoma (launch in Q106), new indications for Hycamtin in relapsed ...
GlaxoSmithKline to Begin Trials for Drugs Nov 30, 2005
Forbes The company said it plans to file a new indication with the FDA for its Hycamtin chemotherapy to treat relapsed cervical and small cell lung cancer. ...
|
|
